Ensysce Biosciences (ENSCW) Non Operating Income (2020 - 2025)
Ensysce Biosciences (ENSCW) reported Non Operating Income of $17338.0 for Q3 2025, up 1.85% year-over-year from $17023.0 in Q3 2024, and down 17.48% quarter-over-quarter from $21011.0 in Q2 2025.
Ensysce Biosciences (ENSCW) Non Operating Income (2020 - 2025) Analysis & Trends
Ensysce Biosciences (ENSCW) has 6 years of Non Operating Income data on file, last reported at $17338.0 in Q3 2025.
- Non Operating Income for Q3 2025 came in at $17338.0, up 1.85% year-over-year; the trailing twelve-month figure through Sep 2025 was -$1.2 million (up 5.8% YoY), and the FY2024 annual result was -$1.3 million, down 8250.94% from the prior year.
- Non Operating Income fell to $17338.0 in Q3 2025 per ENSCW's latest filing, from $21011.0 in the prior quarter.
- Over five years, Non Operating Income peaked at $3.9 million in Q1 2022 and troughed at -$1.3 million in Q1 2024.
- A 5-year average of $31588.7 and a median of $7394.0 in 2024 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2022 and 2024: Non Operating Income jumped 1094.24% in 2022, then slumped 23602.47% in 2024.
- A 5-year view of Non Operating Income shows it stood at -$344037.0 in 2021, then jumped by 119.4% to $66729.0 in 2022, then sank by 111.93% to -$7962.0 in 2023, then tumbled by 15530.02% to -$1.2 million in 2024, then soared by 101.39% to $17338.0 in 2025.
- Business Quant data shows ENSCW's Non Operating Income at $17338.0 in Q3 2025, $21011.0 in Q2 2025, and $21939.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 5.75 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 444,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 9.35 Mn |
| 10 | Ensysce Biosciences | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 17,338.00 |
| Jun 30, 2025 | 21,011.00 |
| Mar 31, 2025 | 21,939.00 |
| Dec 31, 2024 | -1.24 Mn |
| Sep 30, 2024 | 17,023.00 |
| Jun 30, 2024 | 7,394.00 |
| Mar 31, 2024 | -1.27 Mn |
| Dec 31, 2023 | -7,962.00 |
| Sep 30, 2023 | 6,934.00 |
| Jun 30, 2023 | 54,652.00 |
| Mar 31, 2023 | 5,419.00 |
| Dec 31, 2022 | 66,729.00 |
| Sep 30, 2022 | 8,679.00 |
| Jun 30, 2022 | -867,937.00 |
| Mar 31, 2022 | 3.85 Mn |
| Dec 31, 2021 | -344,037.00 |
| Sep 30, 2021 | 994,171.00 |
| Jun 30, 2021 | -347,566.00 |
| Mar 31, 2021 | -387,419.00 |
| Dec 31, 2020 | 1.11 Mn |